Akèy › Agammaglobulinemi
Etid klinik pou Agammaglobulinemi ap rekrite nan Etazini
6 etid pou Agammaglobulinemi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05645107Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07220915Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06976476Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)
Ap rekriteEtid obsèvasyon
Laj 2 a 120 · Tout sèks · Mizajou Sep 1, 2026 · NCT00001244IVIG vs SCIG in CIDP
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Dec 11, 2025 · NCT05584631Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.